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O1: Application of whole exome sequencing
for the identification of breast cancer susceptibility
genes
Ian Campbell, Jason Ellul, Jason Li, Maria Doyle and Ella
Thompson
Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne,
Victoria, Australia.
The ability to identify disease-causing mutations in high risk breast
cancer families has broad implications for those affected, in terms of
risk assessment and management as well as treatment. With as much
as 75% of the excess familial risk of breast cancer yet to be attributed
to genetic variants it is likely that additional moderate to high risk
breast cancer genes remain to be discovered. Recent advances in
technology have opened up the possibility of using massively parallel
short-read (or ‘next generation’) sequencing to uncover predisposing
mutations in individuals with inherited cancer in an unbiased manner.
We are performing whole exome sequence analysis of germline
DNA from multiple affected relatives from over 75 high risk non-
BRCA1/non-BRCA2 breast cancer families with the aim of identi-
fying segregating, rare, non-synonymous variants that are likely to
include novel predisposing mutations. Initial experiments using the
NimbleGen Human Exome Array (to capture 180,000 coding exons
and 551 miRNAs) and the Illumina GAIIx platform (combining 75 bp
single end data from three flow cell lanes) generated approximately
3 Gb of mappable sequence data with 54% target specificity. The
average fold-coverage within the target regions was 60X and
importantly, 95% of targeted nucleotides were covered by at least
eight sequence reads. Single nucleotide polymorphisms (SNPs) are
identified using MAQ-SNP and short insertions and deletions (indels)
are identified using novoalign. After excluding all variants reported in
dbSNP, an average of 5 novel nonsense SNPs and 20 frame-shift
indels are identified per index case. The number of nonsense muta-
tions and frameshift indels shared by affected relatives further reduces
the candidate gene list to less than 5 per family.
To date, two potential breast cancer predisposing genes have been
identified. Interestingly, in two families, we identified clearly dele-
terious mutations in BRCA2 and PTEN, respectively. In the BRCA2
family, the index case used for diagnostic BRCA2 sequencing was a
phenocopy and did not carry the mutation. In the case of PTEN, this
gene is known to predispose to breast cancer but curiously none of
these family members showed clinical manifestations of Cowden’s
syndrome. Since PTEN mutation testing is only performed in breast
cancer families if there are Cowden’s syndrome features, it is possible
that PTEN mutation may be under-reported.
Our experience suggests that a proportion of unexplained BRCAx
families may be due to already recognised predisposing genes that
have been missed either because only a single index case and/or only
one or two of the predominant genes have been sequenced. Both these
limitations are enforced due to the current prohibitive cost of con-
ventional mutation detection strategies used in diagnostic laboratories.
Using targeted exome capture it will be possible to simultaneously
sequence all of the top breast cancer predisposing genes in multiple
individuals of a family more rapidly, and at a cost that is less than those
currently incurred when sequencing a single gene like BRCA1. In
summary, whole exome sequencing of multiple individuals from
within each cancer family is proving to be an efficient strategy for
rapidly identifying novel familial predisposing mutations.
O2: Using preimplantation genetic diagnosis to avoid
the inheritance of predisposition to breast cancer
James Marshall, Maria Traversa, Lauren Seeley, Jolene Stockton,
Mark Livingstone and Don Leigh
Sydney IVF, Sydney, NSW, Australia.
Mutations in the genes BRCA1 and BRCA2 are known to be
responsible for increased risk for breast and ovarian cancers and
contribute significantly to an inherited predisposition to breast and
ovarian cancers. Studies suggest an estimated cumulative risk of
breast and ovarian cancer in female gene carriers of 87 and 44%,
respectively (BRCA1) and 84 and 27%, respectively (BRCA2) by age
70, while male carriers reportedly have an elevated risk of prostate or
breast cancers. Preimplantation genetic diagnosis (PGD) can be used
to identify and select for embryos not carrying these mutations.
Nine couples were referred for PGD where the female or her partner
was a known carrier of either a BRCA1 or BRCA2 germ line mutation.
All couples had consultations with an infertility specialist, geneticist,
nurse, scientist and counsellor to ensure informed consent to the pro-
cedures. The PGD tests comprised a number of informative
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polymorphic linkage markers in or around the gene and, where possible,
a specific mutation. Five BRCA1 and 3 BRCA2 couples (average ages
of 29.1 years and 35.0 respectively) proceeded to clinical treatment.
The five BRCA1 couples had a total of 7 IVF-PGD cycles and 2
freeze–thaw cycles. Forty embryos were tested with 28 embryos
identified as mutation free; 6 unaffected embryos were transferred in
5 fresh transfers (2 cycles were freeze-all cycles). A total of 22
embryos were frozen. In addition, 2 embryos were transferred in 2
freeze–thaw cycles. Overall 4 couples achieved an ongoing pregnancy
(including one twin pregnancy) giving a pregnancy rate of (4/7) 57%
per PGD cycle started, and an implantation rate of (5/8) 63%. The
three BRCA2 couples had a total of 3 fresh IVF-PGD cycles. Two
couples only had 1 and 2 oocytes, respectively and so did not proceed
to PGD biopsy and analysis. The remaining couple had 13 embryos
tested with 8 embryos identified as mutation free. One unaffected
embryo was transferred and 7 embryos were frozen. The transfer
resulted in a healthy live born.
PGD provides a viable clinical option to select embryos without
the known, serious cancer predisposition mutation. It can be an
effective and efficient treatment enabling couples to achieve a preg-
nancy free of an inherited BRCA mutation and thus reduce the
psychological burden of consideration of pregnancy termination as
well as eliminating the potential need for future radical prophylactic
surgery for a female child.
O3: Differentially expressed genes in ductal carcinoma
in situ and invasive ductal carcinoma compared
with normal breast tissues
Paturu Kondaiah1, Surekha Damineni1, Neeraj Kumar1, Ravikiran
Reddy Kalathur1, Prasoon Agarwal1, Priyanka Sehgal1, Geetashree
Mukherjee2, Humaira Tabassam2
1Department of Molecular Reproduction, Development and Genetics,
Indian Institute of Science, Bangalore–560012, India. 2Department
of Pathology, Kidwai Memorial Institute of Oncology, Bangalore,
India.
In order to identify differentially expressed genes in breast cancer tis-
sues, we performed microarray hybridizations and analysis of 80 breast
tumor RNAs against pooled normal RNA (20 RNAs) using the Agilent
44 K Oligonucleotide arrays. Amongst these, six tumors were DCIS. A
total of 6,689 genes are differentially regulated with a fold difference of
1.5 (P = 0.01) in DCIS compared to normal breast tissue. Amongst
these 3,282 are up regulated and 3,407 are down regulated. Comparison
of DCIS expressed genes with IDC node positive tumors revealed a total
of 7,004 differentially expressed genes as against 8,001 genes in node
negative tumors. Interestingly DCIS expressed genes forms a distinct
cluster in comparison to other tumors. Several genes previously not
known to be involved in breast cancer showed differential expression in
DCIS. There are several commonly expressed genes between DCIS and
IDC including some of the genes known to be involved in invasion
suggesting the expression of invasive gene signature early on in breast
tumorigenesis. The data along with validations will be presented. To the
best of our knowledge this is the first data set in Indian breast cancer
patients describing gene signatures.
O4: Her2 and the synergistic binding of its antibodies:
in silico insights
G Fuentes1, M SCaltriti2,3, J. Cortes2, J Baselga2,3, C Verma1
1Bioinformatics Instt, 30 Biopolis Street, 07-01 Matrix, Singapore
138671. 2Medical Oncology Department, Vall d’Hebron Institute
of Oncology (VHIO), Barcelona, Spain. 3Division of Hematology
and Oncology, Massachusetts General Hospital, Harvard Medical
School, Boston, MA, USA.
The ErbB family of receptor tyrosine kinase consists of 4 members,
EGFR, Her2, Her3 and Her4. Her2 is amplified/overexpressed in
about 20% of breast cancers and represents an important therapeutic
target in this subset of patients. The use of monoclonal antibodies
targeting Her2 is one of the most efficacious therapeutic approach in
the clinical setting. These molecules include trastuzumab, binding to
domain IV of the Her2 ectodomain and pertuzumab, binding to the
dimerization arm (domain II).
The combination of these two Abs has recently shown unexplained
synergism in clinical trials, where the efficiency over trastuzumab
alone was greatly enhanced.
Computational structural models of the interactions of her2 with
these two antibodies suggest a feasible mechanism to support the
observed synergism and will be discussed. Mutation studies to test
this hypothesis are ongoing.
O5: Investigation of intracellular cancerous
biomarkers: in silico analysis
Kanchi Lakshmi Kiran and S. Lakshminarayanan
Department of Chemical and Biomolecular Engineering, National
University of Singapore, Singapore.
Cancer is a complex disease wherein the comprehension and eluci-
dation of networks involving numerous interconnected pathways
remains a challenging and important task. Over the past 50 years, a lot
of data have been amassed via in vitro, in vivo experiments. The
phenotypic identification of different cancers has proceeded well -
however, very little knowledge of this has been utilized until now to
figure out specific cancerous biomarkers. One key problem has been
that these experiments are not always informative enough to extract
the interactive effect of multiple pathways. In this regard, mathemat-
ical modeling techniques can facilitate in the development and
analysis of the network models from the existing historical data of
different intracellular processes regulating cell division process.
In this work, we developed an integrated mathematical framework
incorporating different intracellular pathways such as glucose metab-
olism, p53 activation, activation of kinase complexes during cell cycle.
Then, we applied global sensitivity analysis techniques on the model to
find the key parameters affecting the unregulated and uncontrolled cell
division. These results can perhaps indicate opportunities in the field of
drug design for the implementation of personalized therapies. In
summary, these kind of in silico based studies can provide supporting
tools for investigating influential mechanisms controlling the cancer
growth and testing different hypotheses.
O6: Silicon nanowire biosensor for detection of protein-
DNA interactions in nuclear extracts from breast
cancer cell
Min Huang Joon1, Guo-Jun Zhang1, Ang Jun’An Jason1, Edison T.
Liu2, Kartiki Vasant Desai2
1Institute of Microelectronics, 11 Science Park Road, Singapore
117685. 2Genome Institute of Singapore, 60 Biopolis Street,
Singapore 138672.
Silicon nanowires (SiNWs) biosensor, as a label-free and highly sen-
sitive electronic detection methodology, has been extensively
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developed for detection of nucleic acids and proteins. However, little is
known about studying of protein-DNA interactions using the SiNW
biosensor. In this work, a self-assembled monolayer (SAM) was formed
on the SiNW surface, and the SAM-assisted SiNW biosensor was
capable of characterizing the protein-DNA interactions with good
specificity and sensitivity. More importantly, the SiNW biosensor was
able to detect the protein-DNA interactions in nuclear extracts from
breast cancer cell.
As a proof-of-concept study, estrogen receptor element (ERE) and
estrogen receptor alpha (ERIˆ±) binding was adopted in the work. The
ERIˆ± contains positive charges in neutral HEPES buffer because pI of
ERIˆ± is approximately 8. The contribution of positive charge to the n-
type SiNW surface induces an increase in conductance. Three
sequences of the EREs were employed in this study. The wild-type
ERE (wt-ERE) carries the palindromic GGTCA half-site with a 3-bp
separation. The mutant ERE (mut-ERE) contains a symmetric base
substitution in each of the ERE half-sites. The scrambled-ERE (non-
ERE) has the sequence in the ERE arms scrambled. Specificity of
ERIˆ±-ERE binding was obtained by applying 1 pM ERIˆ± to the three
ERE-functionalized SiNW surface. A remarkable conductance
increase was obtained when the ERIˆ± was bound to the wt-ERE-
functionalized SiNW biosensor, whereas a negligible response was
observed when the ERIˆ± interacted with the non-ERE. To evaluate the
capability of the SiNW sensor for discrimination between mut-ERE
and wt-ERE, the mut-ERE-functionalized SiNW sensor was incubated
with ERIˆ±. The increase in conductance was much lower than that of
wt-ERE. The high specificity suggests that the unique SAM-assisted
SiNW biosensor allows for label-free discrimination between the wild
type and mutant EREs interacting with ERIˆ±. Subsequently, sensi-
tivity was investigated by applying various concentrations of ERIˆ±
from 1 pM to 1 fM to the wt-ERE-functionalized SiNW sensor. It was
observed that the conductance change dropped as a function of varying
concentration of ERIˆ± and the ultralow concentration of ERIˆ± could
be effectively detected down to 10fM with the SiNW biosensor.
ERIˆ±-DNA interactions in nuclear extracts prepared from MCF-7
breast cancer cells were also investigated. The ERIˆ± knocked down by
siRNA in the same cell line and no ERIˆ± from another negative cell
line (MDA MB 231) gave rise to negligible response.
In this presentation, a SAM-assisted SiNW biosensor has been
developed for the specific and high sensitive characterization of
protein-DNA interactions. The SiNW biosensor is capable of distin-
guishing the base substitutions in ERE half-sites by binding them to
ERIˆ±, and the wt-ERE-functionalized SiNW biosensor is proven to
detect 10 fM of ERIˆ±. The biosensor is capable of detecting the
protein-DNA interactions in nuclear extracts from breast cancer cell,
shedding light on ER-mediated gene expression for breast cancer.
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